Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

Table 2 Effect of cetuximab + FOLFOX4 regimen on the clinical response of advanced gastric carcinoma patients receiving evidence-based care, n (%)

Classification	Research group (n = 60)	Control group (n = 57)	χ2	P value
CR	12 (20.00)	2 (3.51)
PR	39 (65.00)	27 (47.37)
SD	5 (8.33)	17 (29.82)
PD	4 (6.67)	11 (19.30)
RR	51 (85.00)	29 (50.88)	15.740	< 0.001
DCR	56 (93.33)	46 (80.70)	4.173	0.041

FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; RR: Response rate; DCR: Disease control rate.